Business Wire

CA-CIRCLECI

14.3.2024 14:01:34 CET | Business Wire | Press release

Share
CircleCI Launches Release Agent to Automate Release Orchestration

CircleCI, the leading continuous integration and continuous delivery (CI/CD) platform, today unveiled CircleCI releases, which enables developers to automate the release orchestration process directly from the CircleCI UI. With current support for Kubernetes and Amazon SageMaker, developers now have end-to-end visibility of their deployments in production and access to rollback commands (e.g., restore version, scale component, and restart component) for seamless release management. CircleCI releases makes deploying code less risky, user-focused, and more accessible for developers to ship faster with confidence.

Today, developers operate in increasingly complex tech stacks yet are under pressure to move quickly without compromising software quality. As a result, elite engineering teams are incorporating agile development practices like progressive delivery and canary releases, which provide the guardrails necessary for risk-free deployments via the ability to target, segment, and roll back releases. CircleCI releases enables software teams to automate the progressive delivery process with support for Argo Rollouts, giving developers complete control over their releases. Future support for blue-green deployments is slated for later in 2024. By automating CI/CD pipelines directly into the release orchestration process, software teams dramatically reduce mean-time-to-recovery (MTTR), giving them the confidence to resolve issues should releases go awry with little to no impact on their customers.

Key features and benefits of CircleCI releases include:

  • Change validation: Developers can validate the entire change from build to production.
  • User-focused releases and minimized risk: Developers can connect their CI/CD pipeline directly to the customer experience to make releases user-focused, risk-free, and rollback-friendly.
  • Increased code confidence: With automated release orchestration, teams will definitively know that their code is working as intended.
  • Automated rollbacks: Manual rollbacks take 45 minutes to an hour. Automated rollbacks make the delivery process fast, efficient, and streamlined.
  • Real-time service validation: Developers can safely release code to a controlled subset of real users in a live production environment to get immediate feedback on how code performs. Flexible subsets include internal testers, beta customers, or an external low-risk customer group of choice.
  • Performance degradation prevention: Automate your release conditions and best practices into a release policy to act as guardrails. By automating software validation in production and rolling back releases when necessary, developers, operators, and customers are protected from performance degradation.

“If you look at every other deploy and release vendor on the market, they’re built to service centralized release and operations teams who want tighter control over deploys,” said Rob Zuber, CTO of CircleCI. “But this doesn’t reflect the reality of elite software teams who depend on developers to drive and deliver fast innovation. Our approach to CircleCI releases provides a developer-centric workflow that enables them to ship faster and monitor new features in production coupled with the safety net of quickly rolling back releases if something goes wrong.”

CircleCI releases is now available to all CircleCI users. To learn more or chat about how CircleCI can empower your team to deliver innovation faster, visit one of our experts at KubeCon EU, booth M16 from March 19-21, 2024. Get started using CircleCI releases today.

About CircleCI

CircleCI is a leading continuous integration and continuous delivery (CI/CD) platform, enabling more than two million global users on elite engineering teams like Okta, Hinge, and Hugging Face to rapidly build, test, deploy, and monitor software they can trust. Through powerful pipeline automation, CircleCI manages limitless complexity at scale through unmatched flexibility and reliability, reducing the time from build to delivery by 3x the industry average. For more information about CircleCI, visit www.circleci.com or follow us on Twitter, LinkedIn, and YouTube.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240314509917/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release

The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a

SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release

Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye